AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Company Details
- Employees
- 200
- Founded
- -
- Address
- 30 Winter St,
- Phone
- (617) 588-1960
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aveooncology.com
- Keywords
- Oncology.
- HQ
- Boston, Massachusetts
Aveo Oncology Questions
Aveo Oncology's helpline number is (617) 588-1960
Aveo Oncology's website is aveooncology.com
Aveo Oncology's LinkedIn profile is https://www.linkedin.com/company/aveo-oncology
Aveo Oncology has
200 employees.
View email and phone details for 200
employees at Aveo Oncology.
Aveo Oncology's industry is
Biotechnology Research
Aveo Oncology's top competitors are
Strata Oncology,
Precision Oncology .,
Clovis Oncology,
Verastem Oncology,
Elevation Oncology,
Karyopharm Therapeutics Inc.,
Dava Oncology,
Kura Oncology, Inc.,
Aveo Pharmaceutical Limited,
Vertex Pharmaceuticals.
Aveo Oncology's categories are Biotechnology Research
Aveo Oncology's founding year is 2001
